S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
NASDAQ:OCUL

Ocular Therapeutix (OCUL) Stock Price, News & Analysis

$10.88
+0.13 (+1.21%)
(As of 03/4/2024 ET)
Today's Range
$10.30
$11.29
50-Day Range
$3.85
$10.88
52-Week Range
$2.00
$11.29
Volume
2.37 million shs
Average Volume
2.60 million shs
Market Capitalization
$864.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.40

Ocular Therapeutix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
32.4% Upside
$14.40 Price Target
Short Interest
Healthy
5.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.01
Upright™ Environmental Score
News Sentiment
0.66mentions of Ocular Therapeutix in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$7 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.13) to ($0.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

123rd out of 960 stocks

Pharmaceutical Preparations Industry

50th out of 440 stocks


OCUL stock logo

About Ocular Therapeutix Stock (NASDAQ:OCUL)

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OCUL Stock Price History

OCUL Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Brokerages Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) PT at $14.25
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
3 Stocks to Buy That Are Up 100% or More in 2024
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down to $9.70
OCUL Jun 2024 10.000 put
OCUL Mar 2024 7.000 put
OCUL Mar 2024 4.000 put
See More Headlines
Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/04/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OCUL
Employees
274
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.40
High Stock Price Target
$18.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+32.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-71,040,000.00
Net Margins
-116.18%
Pretax Margin
-116.18%

Debt

Sales & Book Value

Annual Sales
$51.49 million
Book Value
$0.46 per share

Miscellaneous

Free Float
75,051,000
Market Cap
$864.09 million
Optionable
Optionable
Beta
1.32
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Antony MattessichMr. Antony Mattessich (Age 56)
    President, CEO & Director
    Comp: $1.05M
  • Mr. Donald Notman Jr.
    Chief Financial Officer
  • Dr. Rabia Gurses Ozden M.D. (Age 56)
    Chief Medical Officer
    Comp: $621.39k
  • Dr. Peter K. Jarrett Ph.D. (Age 67)
    Chief Scientific Officer
  • Mr. Philip C. Strassburger Esq. (Age 64)
    General Counsel
    Comp: $282.61k
  • Mr. William H. Ransone II
    Vice President of Global Sales & Marketing
  • Ms. Tracy Smith
    Vice President of Human Resources
  • Mr. Christopher G. White (Age 62)
    Chief Business Officer
  • Dr. Karen-Leigh Edwards M.B.A.
    Ph.D., Senior Vice President of Technical Operations
  • Dr. Peter K. Kaiser M.D.
    Chief Medical Advisor of Retina














OCUL Stock Analysis - Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings
or view top-rated stocks.

What is Ocular Therapeutix's stock price target for 2024?

5 analysts have issued 1 year price targets for Ocular Therapeutix's stock. Their OCUL share price targets range from $12.00 to $18.00. On average, they predict the company's stock price to reach $14.40 in the next twelve months. This suggests a possible upside of 32.4% from the stock's current price.
View analysts price targets for OCUL
or view top-rated stocks among Wall Street analysts.

How have OCUL shares performed in 2024?

Ocular Therapeutix's stock was trading at $4.46 at the beginning of 2024. Since then, OCUL stock has increased by 143.9% and is now trading at $10.88.
View the best growth stocks for 2024 here
.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.03. The biopharmaceutical company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.13 million. Ocular Therapeutix had a negative trailing twelve-month return on equity of 589.24% and a negative net margin of 116.18%. During the same period in the prior year, the firm posted ($0.17) earnings per share.

What ETFs hold Ocular Therapeutix's stock?

ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Opaleye Management Inc. (7.64%), Vanguard Group Inc. (6.44%), Franklin Resources Inc. (5.67%), Deltec Asset Management LLC (3.08%), Nuveen Asset Management LLC (1.27%) and Great Point Partners LLC (0.88%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Rabia Gurses Ozden, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends
.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCUL) was last updated on 3/5/2024 by MarketBeat.com Staff